C 18 H 20 BrFN 2 O1, monoclinic, P21/c (no. 14), a = 14.1884(10) Å,
T = 273 K.
CCDC no.: 1040490
The crystal structure is shown in the gure. Tables 1 and 2 contain details on crystal structure and measurement conditions and a list of the atoms including atomic coordinates and displacement parameters.
Source of material
The intermediates were obtained by a condensation reaction between the 2-bromo-1-(4-bromophenyl)ethanone and the substituted phenylpiperazine, adding 1.5 times of potassium carbonate in acetonitrile. In the second step, the reduction of intermediates with sodium borohydride in ethanol leads to the formation of the title compound. Colorless block-shaped crystals were obtained by slow evaporation of the solution containing the compound in air.
Experimental details
All hydrogen atoms were placed in calculated positions. 
Discussion
Piperazine derivatives possess a wide spectrum of biological activities like antimicrobial, antituberculosis, anticancer, antiviral and antimalarial activities [1] . Structure-activity relationships showed that phenylpiperazine is an important regional center where α receptors combine with drugs basic center, and these compounds have α receptor blocking activity in di erent degrees. In addition, phenylpiperazine have also been widely used as ligands in the preparation of complexes [2] [3] [4] [5] .
All bond lengths and angle in the title molecule (cf. the gure) are in the normal ranges.
